登录    
  
首页 > 期刊论文 > 论文摘要
重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的临床观察
         
Clinical study of recombinant human vascular endostatin combined with platinum-based chemotherapy in advanced non-small cell lung cancer

摘    要
目的:评价重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的疗效和不良反应。方法:108例晚期非小细胞肺癌患者被随机分入试验组(54例)和对照组(54例)。对照组患者接受含铂化疗方案治疗,试验组患者接受重组人血管内皮抑制素联合含铂化疗方案治疗。观察2组患者的近期有效率和临床获益率以及疾病进展时间和总生存期,并观察治疗前后患者Karnofsky体能状况评分以及血清癌胚抗原水平的变化。结果:试验组的近期有效率为38.46%,对照组为18.87%(P=0.026);试验组的临床获益率为80.77%,对照组为62.26%(P=0.036)。2组患者治疗前后的Karnofsky体能状况评分差异均无统计学意义(P>0.05)。2组患者治疗后的血清癌胚抗原水平均较治疗前明显下降(P<0.05)。试验组的中位疾病进展时间为6.2个月,对照组为4.7个月(P=0.022);试验组的中位总生存期为16.2个月,对照组为14.1个月(P=0.485)。2组患者的不良反应相似,主要为骨髓抑制和消化系统反应等。试验组患者发生心脏毒性的比例高于对照组,但差异无统计学意义(P=0.086)。结论:重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的近期疗效较好,可延长疾病进展时间,且耐受性良好。
标    签   非小细胞肺   重组人血管内皮抑制素   治疗结果   疾病进展时间   生存   Carcinoma   non-small cell lung   Recombinant human vascular endostatin   Treatment outcomes   Time to progression   Survival  
 
Abstract
Objective: To evaluate the efficacy and toxicity of recombinant human endostatin(rhendostatin) combined with platinum-based chemotherapy in advanced non-small cell lung cancer. Methods: One hundred and eight patients with advanced non-small cell lung cancer were randomly divided into study group(n=54; receiving rh-endostatin combined with platinum-based chemotherapy) and control group(n=54; receiving platinum-based chemotherapy). The short-term response rate(RR), clinical benefit rate(CBR), time to progression(TTP) and overall survival(OS) were calculated, and the changes of Karnofsky performance status(KPS) score and serum carcinoembryonic antigen(CEA) level were observed. Results: The short-term RRs of the study group and the control group were 38.46% and 18.87%, respectively(P=0.026); the CBRs of the study group and the control group were 80.77% and 62.26%, respectively(P=0.036). The difference in KPS score before and after treatment had no statistical significance(P>0.05). The serum CEA level was significantly lower after treatment than before treatment in both groups(P<0.05). The TTP was 6.2 months in the study group, while which was 4.7 months in the control group; there was a significant difference between the two groups(P=0.022). The OS in the study group and control group were 16.2 and 14.1 months, respectively(P=0.485). The adverse reactions between the two groups were similar, and the major adverse reactions were bone marrow suppression and gastrointestinal reactions. The rate of cardiotoxicity was higher in the study group than in the control group, but there was no difference between the two groups(P=0.086). Conclusion: The combination of rh-endostatin and platinum-based chemotherapy can lead to a better short-term RR and a superior TTP, and it is also well tolerated.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2012.01.011

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 临床研究

基金项目

收稿日期 2011/11/3

修改稿日期 2011/12/22

网络出版日期

作者单位点击查看


引用该论文: FU Lei,FAN Qing-xia,WANG Liu-xing,QIN Yan-ru,CHEN Jing. Clinical study of recombinant human vascular endostatin combined with platinum-based chemotherapy in advanced non-small cell lung cancer[J]. Tumor, 2012, 32(1): 60~64
付蕾,樊青霞,王留兴,秦艳茹,陈静. 重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的临床观察[J]. 肿瘤, 2012, 32(1): 60~64


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】JEMAL A, SIEGEL R, XU J, et al. Cancer statistics,2010[J]. CA Cancer J Clin, 2010, 60(5):277-300.
 
【2】SCHILLER J H, HARRINGTON D, BELANI C P, et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl JMed, 2002, 346(2):92-98.
 
【3】RITVA H, PIA N, JANI L, et al. Generation of biologically active endostatin fragments from human collagen Ⅹ Ⅴ Ⅲ by distinct matrixmetal loproteases[J]. Exp Cell Res, 2005,307(2):292-304.
 
【4】FOLKMAN J. Role of angiogenesis in tumor growth and metastasis[J]. Semin Oncol, 2002, 29(Suppl16):15-18.
 
【5】TYAGI P. Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previouslyuntreated patients with advanced non-small celllung cancer:preliminary results from theECOG 4599 trial[J]. Clin Lung Cancer, 2005,6(5):276-278.
 
【6】O'REILLY M S, BOEHM T, SHIN G Y, et al.Endos tat in:an endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997,88(2):277-285.
 
【7】王万金, 刘永煜, 张沂平, 等. 重组人血管内皮抑制素联合NP 方案治疗晚期NSCLC 随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志, 2005,8(4):283-290.
 
相关信息
   标题 相关频次
 化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性
 6
 单药培美曲塞二线治疗晚期非小细胞肺癌的疗效观察
 5
 GRIM-19基因对肺腺癌耐药细胞株A549/DDP药物敏感性及相关基因表达的影响
 4
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 4
 Luffin-β靶向融合免疫毒素的构建、表达及对非小细胞肺癌的抑制作用
 4
 RNA干扰沉默乏氧诱导因子-1α对紫杉醇诱导食管鳞癌EC9706细胞凋亡的影响
 4
 siRNA干扰MT1H基因对A549/DDP细胞耐药性的逆转
 4
 非小细胞肺癌组织中血管内皮生长因子表达与树突状细胞分布的关系
 4
 高海拔地区老年非小细胞肺癌患者接受全电视胸腔镜下肺叶切除的安全性和预后分析
 4
 钠氢交换蛋白1基因在体外对食管癌KYSE-70细胞增殖和侵袭作用的影响
 4
 全反式维甲酸对EC9706荷瘤裸鼠抑瘤作用的实验研究
 4
 人肺腺癌细胞株A549和A549/DDP的比较蛋白质组学研究
 4
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 4
 食管鳞癌EC-9706细胞中mTOR信号通路在TGF-β1介导的EMT中的作用
 4
 34例卵巢透明细胞癌临床分析
 3
 多靶点受体酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌的Meta分析
 3
 非小细胞肺癌CD44v6表达的免疫组化研究
 3
 紫杉醇脂质体或常规紫杉醇联合S-1治疗进展期胃癌:药代动力学、疗效及安全性的比较
 3
 2009年恶性肿瘤临床治疗新进展
 2
 28例宫颈癌放疗后主动脉旁淋巴结转移的调强放射治疗
 2
 ALDHs与胰腺癌以及胰腺癌干细胞的研究进展
 2
 Autotaxin在人卵巢癌基因及蛋白水平表达的研究及意义
 2
 C-myc蛋白在睾丸肿瘤中的表达及意义
 2
 cRGD-氧化铁纳米粒的构建及应用于核磁共振成像诊断中的动物研究
 2
 癌症的远古性及其理论和实践意义
 2
 膀胱移行细胞癌中cPKCα的表达及意义
 2
 表达FasL的肝癌细胞通过Fas/FasL诱导T淋巴细胞发生凋亡
 2
 沉默DNAJB11基因对肝癌SMMC7721细胞增殖、周期与凋亡的影响
 2
 沉默脂肪甘油三酯脂肪酶基因表达可抑制肝细胞癌细胞的增殖、迁移与侵袭
 2
 大姚县青石棉污染区恶性肿瘤死亡27年回顾性队列研究
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2